Skip to main content

ACTolog in Patients With Solid Cancers

Trial Status: Closed to Accrual

The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express collagen VI alpha 3 (COL6A3) exon 6, preferentially expressed antigen in melanoma (PRAME), melanoma-associated antigen 1 (MAGEA1), melanoma-associated antigen 4 (MAGEA4), melanoma-associated antigen 4 or 8 (MAGEA4 / 8), cancer / testis antigen 1A / New York esophageal squamous cell carcinoma 1 (CTAG1A / NY-ESO-1), or matrix remodeling-associated protein 5 (MXRA5).

Inclusion Criteria

  • Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment.
  • HLA phenotype positive.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Life expectancy > 6 months prior to enrollment.
  • Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog).
  • The patient has adequate organ and marrow function per protocol
  • At least one lesion (metastasis or primary tumor) being considered accessible by non-high-risk collection procedures for biopsy.
  • The patient has adequate hepatic function per protocol
  • The patient has serum creatinine clearance ≥50 mL/min by the Cockcroft-Gault formula.
  • The patient has adequate pulmonary function per protocol and oxygen saturation >92% on room air.
  • Acceptable coagulation status: INR ≤2.0 x ULN and PTT ≤2.0 x ULN.
  • Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  • Male subjects must agree to use effective contraception or abstinence while on study and for 90 days after infusion of the ACTolog T-cell product.
  • Ability of subject to understand and the willingness to sign written informed consent for study participation.
  • Confirmed availability of production capacities for the patient's ACTolog products.
  • ACTolog target expression as evaluated by the in vitro diagnostic device IMA_Detect: Patient's tumor must express at least one ACTolog target as assessed by quantitative PCR (qPCR) (to be assessed from a tumor biopsy to be performed if all other eligibility criteria are met).

Exclusion Criteria

  • Any condition contraindicating leukapheresis.
  • Patients with brain metastases. Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis.
  • HIV infection, active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included.
  • The patient has received chemotherapy, surgery, radiotherapy (for therapeutic purposes), tyrosine kinase inhibitor (TKI) (e.g. erlotinib, gefitinib), investigational drugs, chronic use of systemic corticosteroids or statin therapy within 2 weeks prior to leukapheresis.
  • Previous extensive radiotherapy to the lung or liver during the last 4 months prior to lymphodepletion regimen.
  • The patient has cardiac conditions defined per protocol
  • Patients with prior stem cell transplantation or solid organ transplantation.
  • The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
  • Active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.
  • The patient is pregnant or is breastfeeding.
  • Serious autoimmune disease: Patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) or autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic Lupus Erythematosus or autoimmune vasculitis [e.g. Wegener's Granulomatosis] are excluded from this study.
  • History of hypersensitivity to cyclophosphamide, fludarabine or IL-2.
  • Immunosuppression, not related to prior treatment for malignancy.
  • History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
  • Patients with Grade 3 or higher immune-related toxicities related to prior checkpoint inhibitors

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) and the main biomarkers screening. If the patient is eligible, white blood cells will be collected with a leukapheresis for the manufacture of the IMA101 product. MANUFACTURE: IMA101 product will be made from the patient's white blood cells. TREATMENT: IMA101 product will be administered to the patient intravenously after lymphodepleting pre-conditioning with chemotherapy (fludarabine and cyclophosphamide). Low-dose IL-2 will be self-administered twice daily for a total of 28 doses after infusion of IMA101 product. In Cohort 2, atezolizumab will be administered every 3 weeks, starting no earlier than 3 weeks after the IMA101 product infusion and after hematologic recovery. Patients will be monitored closely throughout the study.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Immatics US, Inc.

  • Primary ID IMA101-101
  • Secondary IDs NCI-2018-00201
  • Clinicaltrials.gov ID NCT02876510